A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

Preclinical data have shown that the herbal extract, ALS-L1023, from <i>Melissa officinalis</i> reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week random...

Full description

Bibliographic Details
Main Authors: Gi-Ae Kim, Hyun Chin Cho, Soung Won Jeong, Bo-Kyeong Kang, Mimi Kim, Seungwon Jung, Jungwook Hwang, Eileen L. Yoon, Dae Won Jun
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceuticals
Subjects:
ALS-L1023
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
Online Access:https://www.mdpi.com/1424-8247/16/4/623

Internet

https://www.mdpi.com/1424-8247/16/4/623

Similar Items